Clinical Trial Update: Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 safety and cognitive function trial of EVP-6124 (encenicline) in mild-to-moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• EVP-6124

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Alzheimer's Disease, Central Nervous System Diseases | Phase 2 | Status: COMPLETED